Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,945,151
  • Shares Outstanding, K 76,240
  • Annual Sales, $ 0 K
  • Annual Income, $ -182,390 K
  • EBIT $ -256 M
  • EBITDA $ -252 M
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.69

Options Overview Details

View History
  • Implied Volatility 59.24% ( +5.88%)
  • Historical Volatility 41.88%
  • IV Percentile 81%
  • IV Rank 75.59%
  • IV High 70.82% on 01/17/24
  • IV Low 23.39% on 08/21/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 30
  • Volume Avg (30-Day) 100
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 2,379
  • Open Int (30-Day) 2,248

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.89
  • Number of Estimates 9
  • High Estimate -0.79
  • Low Estimate -1.02
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -39.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.52 +2.96%
on 12/19/24
43.49 -11.19%
on 11/29/24
-0.71 (-1.80%)
since 11/20/24
3-Month
37.34 +3.45%
on 11/19/24
46.00 -16.02%
on 11/08/24
-1.52 (-3.79%)
since 09/20/24
52-Week
35.53 +8.73%
on 06/26/24
50.99 -24.24%
on 03/01/24
-2.37 (-5.78%)
since 12/20/23

Most Recent Stories

More News
Xenon Pharmaceuticals Reports Long-Term Efficacy and Safety Data for Azetukalner in Open-Label Extension Study at AES 2024

Xenon Pharmaceuticals reports long-term efficacy and safety of azetukalner for focal onset seizures, showing significant seizure reduction and patient well-being.Quiver AI SummaryXenon Pharmaceuticals...

XENE : 38.63 (-0.69%)
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

XENE : 38.63 (-0.69%)
Xenon Pharmaceuticals Inc. Announces Multiple Poster Presentations at AES 2024 Featuring New Data on Azetukalner and Nav1.1 Program

Xenon Pharmaceuticals will present five posters at the AES 2024 showcasing new data on azetukalner and mental health burdens in epilepsy.Quiver AI SummaryXenon Pharmaceuticals Inc. announced that it will...

XENE : 38.63 (-0.69%)
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

XENE : 38.63 (-0.69%)
Xenon to Present at Upcoming Investor Conferences

XENE : 38.63 (-0.69%)
Xenon Pharmaceuticals: Q3 Earnings Snapshot

Xenon Pharmaceuticals: Q3 Earnings Snapshot

XENE : 38.63 (-0.69%)
Xenon Reports Q3 2024 Financial Results and Business Update

XENE : 38.63 (-0.69%)
Xenon to Report Q3 2024 Financial Results on November 12, 2024

XENE : 38.63 (-0.69%)
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed...

ITCI : 83.45 (-0.82%)
XENE : 38.63 (-0.69%)
AXSM : 90.73 (+1.10%)
Xenon Pharmaceuticals: Q2 Earnings Snapshot

Xenon Pharmaceuticals: Q2 Earnings Snapshot

XENE : 38.63 (-0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan...

See More

Key Turning Points

3rd Resistance Point 40.85
2nd Resistance Point 40.16
1st Resistance Point 39.39
Last Price 38.63
1st Support Level 37.93
2nd Support Level 37.24
3rd Support Level 36.47

See More

52-Week High 50.99
Fibonacci 61.8% 45.08
Fibonacci 50% 43.26
Fibonacci 38.2% 41.44
Last Price 38.63
52-Week Low 35.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar